GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    [18F]DCFPyL PET/CT for Imaging of Prostate Cancer
    Georg Thieme Verlag KG ; 2022
    In:  Nuklearmedizin - NuclearMedicine Vol. 61, No. 03 ( 2022-06), p. 240-246
    Details
    In: Nuklearmedizin - NuclearMedicine, Georg Thieme Verlag KG, Vol. 61, No. 03 ( 2022-06), p. 240-246
    Abstract: Prostate-specific membrane antigen (PSMA)-directed positron emission tomography (PET) has gained increasing interest for imaging of men affected by prostate cancer (PC). In recent years, 68Ga-labeled PSMA compounds have been widely utilized, although there is a trend towards increased utilization of 18F-labeled agents. Among others, [18F]DCFPyL (piflufolastat F 18, PYLARIFY) has been tested in multiple major trials, such as OSPREY and CONDOR, which provided robust evidence on the clinical utility of this compound for staging, restaging, and change in management. Recent explorative prospective trials have also utilized [18F] DCFPyL PET/CT for response assessment, e.g., in patients under abiraterone or enzalutamide, rendering this 18F-labeled PSMA radiotracer as an attractive biomarker for image-guided strategies in men with PC. After recent approval by the U.S. Food and Drug Administration, one may expect more widespread use, not only in the U.S., but also in Europe in the long term. In the present review, we will provide an overview of the current clinical utility of [18F]DCFPyL in various clinical settings for men with PC.
    Type of Medium: Online Resource
    ISSN: 0029-5566 , 2567-6407
    URL: Article
    DOI: 10.1055/a-1659-0010
    Language: English
    Publisher: Georg Thieme Verlag KG
    Publication Date: 2022
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Clinical Utility of C-Reactive Protein and White Blood Cell Count for Scheduling an [18F]FDG PET/CT in Patients with Giant Cell Arteritis
    Georg Thieme Verlag KG ; 2022
    In:  Nuklearmedizin - NuclearMedicine Vol. 61, No. 06 ( 2022-12), p. 425-432
    Details
    In: Nuklearmedizin - NuclearMedicine, Georg Thieme Verlag KG, Vol. 61, No. 06 ( 2022-12), p. 425-432
    Abstract: Objectives 2-deoxy-2-[18F]fluoro-D-glucose ([18F] FDG) PET/CT can be utilized in patients with giant cell arteritis (GCA), but pretest probability of established laboratory marker such as C-reactive protein (CRP) and white blood cell count (WBC) has not been defined yet. We aimed to elucidate the clinical utility of CRP and WBC for scheduling an [18F]FDG scan. Methods 18 treatment-naïve GCA patients and 14 GCA subjects with anti-inflammatory treatment (glucocorticoids or comparable drugs), who underwent [18F]FDG PET/CT and who had no other inflammatory disease at time of scan, were identified. A semi-quantitative analysis in 11 vessel segments was conducted, with averaged jugular vein, healthy liver and lung tissue (Target-to-background ratio [TBR] VJ/liver/lung) serving as background. Derived TBR were then correlated with CRP and WBC at time of PET using Spearman’s correlation. Results For all treatment-naïve patients, TBRVJ was 2.3±1.1 (95%CI, 2.2–2.5), TBRliver was 1.0±0.5 (95%CI, 0.9–1.0) and average TBRlung was 6.3±3.6 (95%CI, 5.8–6.8). No significant correlation was noted for either CRP (TBRVJ: R=–0.19; TBRliver: R=–0.03; TBRlung: R=–0.17; each P ≥ 0.44) or for WBC (TBRVJ: R=–0.40; TBRliver: R=–0.32; TBRlung: R=–0.37; each P ≥ 0.10). Similar results were recorded for patients under treatment at time of PET. Again, no significant correlation was reached for either CRP (TBRVJ: R=–0.17; TBRliver: R=–0.28; TBRlung: R=–0.09; each P ≥ 0.32) or WBC (TBRVJ: R=–0.06; TBRliver: R=–0.13; TBRlung: R=0.06; each P ≥ 0.65). Conclusions In GCA patients with and without anti-inflammatory treatment, CRP and WBC did not substantially correlate with TBR at time of scan. Given the rather limited pretest probability of those parameters, such laboratory values may have less diagnostic utility to order an [18F]FDG PET/CT.
    Type of Medium: Online Resource
    ISSN: 0029-5566 , 2567-6407
    URL: Article
    DOI: 10.1055/a-1830-7767
    Language: English
    Publisher: Georg Thieme Verlag KG
    Publication Date: 2022
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    PET-Derived Increased Inflammation in Large Vessels is linked to Relapse-Free Survival in Patients with Giant Cell Arteritis
    Georg Thieme Verlag KG ; 2023
    In:  Nuklearmedizin - NuclearMedicine Vol. 62, No. 04 ( 2023-08), p. 229-234
    Details
    In: Nuklearmedizin - NuclearMedicine, Georg Thieme Verlag KG, Vol. 62, No. 04 ( 2023-08), p. 229-234
    Abstract: Background Despite anti-inflammatory treatment, patients with giant cell arteritis (GCA) experience relapse. We aimed to determine respective relapse predictors focusing on [18F]fluorodeoxyglucose ([18F] FDG)-PET-based parameters. Material and Methods 21 therapy-naïve GCA patients received [18F]FDG-PET/CT. Patients were divided in two groups: those who relapsed during course of disease and those who did not. Median follow up was 15 months. [18F] FDG-PET/CT was analyzed for visual (PET vascular activity score [VAS]) and quantitative parameters, including Target-to-background-Ratio with liver (TBRliver) and jugular vein (TBRjv) serving as reference tissues. In addition, clinical parameters were tested. Results 8/21 (38.1 %) had relapse. Clinical parameters could not significantly discriminate between relapse vs no-relapse, including age (p = 0.9) or blood-based inflammatory markers (white blood cell counts [WBC] and c-reactive protein [CRP] , p = 0.72, each). PETVAS score could also not differentiate between respective subgroups (p = 0.59). In a quantitative assessment, TBRjv demonstrated a trend towards significance (p = 0.28). TBRliver, however, separated between patients with and without relapse (p = 0.03). Conclusion [18F]FDG PET quantification of vessels may be useful to identify GCA patients prone to relapse during follow-up.
    Type of Medium: Online Resource
    ISSN: 0029-5566 , 2567-6407
    URL: Article
    DOI: 10.1055/a-2053-7191
    Language: English
    Publisher: Georg Thieme Verlag KG
    Publication Date: 2023
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Peptidradiorezeptor-Therapie (PRRT)
    Georg Thieme Verlag KG ; 2021
    In:  Der Nuklearmediziner Vol. 44, No. 04 ( 2021-12), p. 334-343
    Details
    In: Der Nuklearmediziner, Georg Thieme Verlag KG, Vol. 44, No. 04 ( 2021-12), p. 334-343
    Abstract: Neuroendokrine Neoplasien (NEN) stellen ein komplexes, heterogenes Krankheitsbild dar, wobei der Primärtumorlokation meist im Gastrointestinaltrakt lokalisiert ist. Als „Orphan Disease“ sind NEN zwar selten, werden aber primär durch eine verbesserte bildgebende Diagnostik in den letzten Jahren verstärkt diagnostiziert. Hierbei spielt die Somatostatinrezeptor (SSTR)-gerichtete molekulare Bildgebung eine große Rolle, insbesondere die Einzelphotonen-Emissions-Computertomografie (SPECT) sowie die Positronen-Emissions-Tomografie (PET). Neben einer exakten Ausbreitungsdiagnostik generiert die SSTR-gerichtete Bildgebung auch eine Therapierationale für eine Peptidradiorezeptortherapie (PRRT) in einem sog. „theranostischen“ Ansatz. Hierbei wird ein β-Strahler mit dem identischen Peptid des diagnostischen SPECT-/PET-Gegenstücks gekoppelt, um somit eine gezielte, SSTR-gerichtete Bestrahlung von NEN und metastatischer Läsionen zu ermöglichen. Das daraus resultierende „heiße“ Somatostatinanalogon kann als hocheffektives Radiotherapeutikum mit akzeptablem Nebenwirkungsprofil eingesetzt werden, was bereits in einer randomisierten, prospektiven, multizentrischen Studie belegt wurde. Die PRRT erfolgt in Deutschland stationär auf einer nuklearmedizinischen Isotopenstation, wobei Indikation, Durchführung und Nachsorge dieser zielgerichteten Therapie in einem interdisziplinären Ansatz in enger Absprache mit Kolleg*innen der Inneren Medizin, der Medizinphysik und Nuklearmedizin erfolgen sollte. Mit Lutathera (177Lu-Oxodotreotid) steht seit Kurzem ein in Deutschland zugelassenes Arzneimittel zur SSTR-gerichteten Therapie zur Verfügung, womit die PRRT verstärkt Anwendung finden dürfte.
    Type of Medium: Online Resource
    ISSN: 0723-7065 , 1439-5800
    URL: Article
    DOI: 10.1055/a-1556-8323
    Language: German
    Publisher: Georg Thieme Verlag KG
    Publication Date: 2021
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Hyponatremia in the Hospital Setting: Interim Results from a Prospective, Observational, Multi-Center, Global Registry
    Georg Thieme Verlag KG ; 2013
    In:  Pneumologie Vol. 67, No. S 01 ( 2013-2-27)
    Details
    In: Pneumologie, Georg Thieme Verlag KG, Vol. 67, No. S 01 ( 2013-2-27)
    Type of Medium: Online Resource
    ISSN: 0934-8387 , 1438-8790
    URL: Issue
    URL: Journal
    URL: Article
    DOI: 10.1055/s-003-24591
    DOI: 10.1055/s-00000059
    DOI: 10.1055/s-0033-1334576
    Language: German
    Publisher: Georg Thieme Verlag KG
    Publication Date: 2013
    detail.hit.zdb_id: 2037091-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...